Amylyx declares late-stage win with a GLP-1 antagonist in its post-ALS reset

Amylyx has reported a successful Phase 3 clinical trial for avexitide, a GLP-1 antagonist, targeting post-bariatric hypoglycemia, indicating potential late-stage efficacy and commercial opportunity.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.